Kymera Therapeutics KYMR Finance Lease Liabilities (Total)
Finance Lease Liabilities (Total) at other companies
Other financials
Where this comes from
Reported directly by Kymera Therapeutics in its filing.
Tagged under the XBRL concept us-gaap:FinanceLeaseLiability.
The official record: Kymera Therapeutics’s 10-Q, filed April 30, 2026, on SEC EDGAR. View the filing →
Ask your AI about Kymera Therapeutics's finance lease liabilities (total).
Connect your AI assistant and compare it to peers, right in your chat.
Connect your AI
Claude
Questions, answered.
- What is Kymera Therapeutics's finance lease liabilities (total)?
- Kymera Therapeutics (KYMR) reported finance lease liabilities (total) of $2.85M in Q1 2026.
- How has Kymera Therapeutics's finance lease liabilities (total) changed year-over-year?
- Kymera Therapeutics's finance lease liabilities (total) decreased by 17.7% year-over-year, from $3.47M to $2.85M.
- What is the long-term trend for Kymera Therapeutics's finance lease liabilities (total)?
- Over 5 years (2020 to 2025), Kymera Therapeutics's finance lease liabilities (total) has grown at a 20.4% compound annual growth rate (CAGR), from $1.29M to $3.28M.
- What does finance lease liabilities (total) mean?
- Finance lease liabilities (total) represent the aggregate present value of all future lease payments for assets where the company assumes substantially all risks and rewards of ownership. This metric reflects the long-term debt-like burden associated with financing infrastructure or equipment through leases. It is a key component of the company's total leverage profile.